|
**Overview**: **Hemogram Mumbai Profile****Introduction**: The Hemogram Mumbai Profile is a diagnostic tool designed to conduct hematology screening with malaria parasite using whole blood samples. Associated with conditions like malaria and anemia, these disorders present with fever, fatigue, and severe complications if untreated, particularly in individuals with hematological or infectious concerns. Per the 2023 Hematology guidelines, the test employs hematology with automated cell counter technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for routine check-ups in clinical settings. This diagnostic falls under routine check-up and targets individuals with suspected hematological or malaria-related disorders, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its blood-based approach ensures reliable detection.**Other Names**: Hemogram Mum Pfl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1970s by hematology labs, this test advanced malaria-integrated blood diagnostics.**Purpose**: The test screens for 22 parameters including hemoglobin to guide hematological and malaria assessment, assess blood cell status and parasitic presence, and inform treatment and prevention strategies.**Test Parameters**: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. Hematocrit, 6. MCV, 7. MCH, 8. MCHC, 9. RDW, 10. Neutrophils, 11. Lymphocytes, 12. Monocytes, 13. Eosinophils, 14. Basophils, 15. ESR, 16. Peripheral Smear, 17. Absolute Neutrophil Count, 18. Absolute Lymphocyte Count, 19. Absolute Monocyte Count, 20. Absolute Eosinophil Count, 21. Reticulocyte Count, 22. Malaria Parasite.**Pretest Condition**: No fasting required; patients should report fever, fatigue, or recent hematological/infectious symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not specified, immediate processing recommended to preserve cell integrity.**Medical History**: Patients should provide details on fever, fatigue, prior hematological or infectious reactions, or family history of blood/malaria disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated conditions including organ damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using automated cell counter and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antimalarial use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hematological or malaria disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in hematology or infectious disease should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Malaria rapid test or blood smear for confirmation.**Test Limitations**: The test may produce false negatives in early infection stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Hematology Guidelines 2023, Journal of Infectious Diseases 2024, Biochemistry 2025. |
